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A B S T R A C T
Background: Buprenorphine is approved in many countries for the treatment of opioid use disorder (OUD), but
problems with diversion and abuse exist. There is a need to understand how and why patients use diverted
buprenorphine, and whether barriers to access contribute to illicit use.
Methods: Adults> 18 years with DSM-IV criteria for substance use disorder and primarily using an opioid
completed the online Survey of Key Informants’ Patients (SKIP) between August and September 2016. The
survey included closed- and open-ended questions regarding reasons for buprenorphine use with and without a
prescription, sources of buprenorphine, route of administration, and barriers to treatment.
Results: Of 303 respondents, 175 (58%) reported a history of diverted buprenorphine use, 65 (37%) of whom
reported never receiving a prescription. The most common reasons for illicit buprenorphine use were consistent
with therapeutic use: to prevent withdrawal (79%), maintain abstinence (67%), or self-wean off drugs (53%).
Approximately one-half (52%) reported using buprenorphine to get high or alter mood, but few (4%) indicated
that it was their drug of choice. Among respondents who had used diverted buprenorphine, 33% reported that
they had issues finding a doctor or obtaining buprenorphine on their own. Most (81%) of these participants
indicated they would prefer using prescribed buprenorphine, if available.
Conclusions: Although 58% of survey respondents reported a history of using diverted buprenorphine, the most
frequently cited reasons for non-prescription use were consistent with therapeutic use. Diversion was partially
driven by barriers to access, and an unmet need for OUD treatment persists.
1. Introduction
Buprenorphine is a μ-opioid receptor partial agonist (Bloms-Funke
et al., 2000) approved by the US Food and Drug Administration (FDA)
for the treatment of opioid use disorder (OUD). At low doses, bupre-
norphine has effects similar to μ-opioid full agonists; at high doses there
is a ceiling on its agonist activity (Walsh et al., 1994). As higher doses
are reached, partial agonists function as antagonists—occupying re-
ceptors without activating them (or partially activating them)—while
simultaneously displacing or blocking full agonists from binding the
receptors (Greenwald et al., 2003). The partial agonist profile of bu-
prenorphine coupled with its high affinity for the μ-opioid receptor may
contribute to a favorable safety profile over μ-opioid receptor full
agonists, particularly with respect to respiratory depression and fatal
overdose.2 The pharmacology also suggests that buprenorphine may
have less abuse liability compared with μ-opioid full agonists (Walsh
et al., 1994) supported by the fact that when available, μ-opioid full
agonists are preferred for illicit use over buprenorphine formulations
(Alho et al., 2007; Comer et al., 2010; Degenhardt et al., 2009; Strain
et al., 2000; Vicknasingam et al., 2010) and is reflected in the Drug
Enforcement Administration (DEA) categorization of buprenorphine as
a Schedule III substance versus Schedule II for most μ-opioid full ago-
nists.
Despite its pharmacologic profile, abuse, misuse, and diversion of
buprenorphine have been documented in the United States (Lavonas
et al., 2014; Monte et al., 2009) and many regions worldwide (Bruce
et al., 2009; Havnes et al., 2013; Kumar et al., 2000; Larance et al.,
2016; Lofwall and Walsh, 2014; Yokell et al., 2011). A recent study has
shown that among patients entering treatment for OUD in the US, the
proportion who used buprenorphine to “get high” nearly quadrupled
from 2008 to 2013 (Cicero et al., 2014).
It is unclear why buprenorphine abuse, misuse, and diversion are so
prevalent among opioid abusers given the widespread availability of μ-
opioid full agonists, particularly in the US. Survey data from current
and former opioid users indicate that diverted buprenorphine is often
used for the intended therapeutic purpose of treating/preventing
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withdrawal symptoms, as a substitute to get high when more preferred
drugs were unavailable, and/or because other OUD treatment was un-
affordable (Bazazi et al., 2011; Cicero et al., 2014). Several interna-
tional studies also indicate that many of those who use diverted bu-
prenorphine do so to prevent withdrawal or to stop using other opioids
(Yokell et al., 2011). Barriers to access through medical channels might
contribute to this diversion, (Lofwall and Havens, 2012) and treatment
program costs and lack of prescribing physicians may deter users from
seeking licensed buprenorphine medical treatment (Bazazi et al., 2011).
In the US, prescription waivers can be obtained by healthcare pro-
viders for Schedule III, IV, and V medications approved by the FDA to
treat OUD. These waivers, made available through the Drug Addiction
Treatment Act of 2000 (DATA 2000)Drug Addiction Treatment Act,
2000Drug Addiction Treatment Act of 2000 (DATA 2000), were in-
tended to integrate addiction treatment into medical offices and other
appropriate settings (Drug Addiction Treatment Act (DATA) of 2000).
Initially, DATA-waived physicians could prescribe buprenorphine to 30
total patients; in 2007, the limit was raised to 100 for physicians with at
least one year of experience. In 2016, the Comprehensive Addiction and
Recovery Act (CARA) further raised the limit to 275 patients and ex-
tended waiver privileges to qualified nurse practitioners and physician
assistants, with patient limits as allowed by state law (Comprehensive
Addiction and Recovery Act (CARA) of 2016). However, there are still a
limited number of physicians in the US with DATA waivers. Moreover,
only 44–66% of these physicians prescribe buprenorphine, and most do
not prescribe to their maximum patient limit (Hutchinson et al., 2014;
Kissin et al., 2006; Kunins et al., 2013; McCarty et al., 2004; Walley
et al., 2008). This unused capacity may be related to physician re-
luctance to add office-based opioid treatment due to lack of time,
payment (insufficient reimbursement) and pharmacy issues; concerns
about medication diversion and resistance from staff or colleagues;
increased administrative and clinical resources (e.g., nursing support);
deficits in knowledge about opioid treatment; lack of belief in agonist
treatment; and/or fear of taking on increased medicolegal risks (Huhn
and Dunn, 2017; Walley et al., 2008). More than half of DATA-waivered
physicians who are not prescribing to capacity report that nothing
would increase their willingness to prescribe more buprenorphine
(Huhn and Dunn, 2017) suggesting that numbers of waivers are un-
likely to increase unless healthcare professionals are provided with
resources and information to sufficiently address their concerns.
To better inform policies and practices that affect the availability of
buprenorphine for OUD treatment, more information is needed about
the reasons for its abuse, misuse, and diversion. The purpose of this
study was to examine motivations for use of diverted buprenorphine
products and explore the role of unmet need for treatment.
2. Methods
2.1. Study sample
Data were from the Researched Abuse, Diversion and Addiction-
Related Surveillance (RADARS®) System, a comprehensive series of
programs that collect and analyze post-marketing data on the misuse
and diversion of prescription opioid analgesics and heroin (Cicero et al.,
2007a; Dart et al., 2015).
The Survey of Key Informants’ Patients (SKIP) Program comprises
treatment centers (Key Informants) that recruit patients entering
treatment for OUD to complete an anonymous survey on opioid misuse
patterns and related behaviors. Survey participants must be 18 years or
older and meet Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV) criteria for substance abuse or dependence with a
primary drug that is an opioid (prescription or heroin).
The Researchers and Participants Interacting Directly (RAPID)
Program consists of a subset of participants from the ongoing nation-
wide SKIP Program. These participants indicated by a mail-in postcard
(provided with the SKIP survey) that they were willing to give up their
anonymity and, following completion of a registration that includes
written consent, participate in the RAPID program. RAPID participants
complete online surveys (hosted by SurveyMonkey®) that included: (1)
direct, quantitative questions based on SKIP analyses and prior litera-
ture on the topic; and (2) open-ended, qualitative essay-style questions
used to explain, in greater detail, participants’ responses to quantitative
questions. From 2008-3q18, there were a total of 21,087 SKIP partici-
pants, who were given a postcard to return if they were interested in
future follow-up studies. A total of 10,445 postcards were received from
interested SKIP participants. Of these, 3885 were eligible to be con-
tacted for the RAPID program (after excluding those with no email, a
working email, illegible/incomplete postcards, duplicates, etc.).
A total of 654 eligible respondents were registered and consented
with the RAPID program and were sent the RAPID survey for this study.
Data for the current study were collected from a five-part RAPID
survey that ran from August 15, 2016 to September 19, 2016 and asked
a series of questions concerning: (1) use of buprenorphine prescribed by
a physician to treat opioid addiction; (2) use of diverted buprenorphine
(i.e., buprenorphine without a prescription); (3) barriers to buprenor-
phine access; (4) buprenorphine formulation preferences among those
with a history of using buprenorphine, with or without a prescription;
and (5) demographics and characteristics of respondents. This survey
focused on use of buprenorphine (with and without a prescription),
reasons for diverted buprenorphine use, sources of diverted buprenor-
phine, routes of administration, and barriers to treatment in the past
year and lifetime of the respondent. Participants in the RAPID program
were compensated with a $20 Wal-Mart gift card. All protocols were
approved by the WUSTL Institutional Review Board (IRB).
2.2. Statistical analysis
Each survey response was reviewed by the authors for completeness
and consistency. Descriptive statistics were used to summarize survey
responses. No inferential testing was completed. Data analysis was
completed using IBM SPSS Statistics v.22 for quantitative data and
NVivo v.10 for qualitative data.
3. Results
3.1. Survey respondents
Of 303 patients who responded to the RAPID survey, 53 (18%) used
buprenorphine exclusively through a physician’s prescription (Fig. 1). A
total of 175 respondents had a history of diverted buprenorphine use,
65 (37%) of whom never received a prescription. Seventy-five re-
spondents reported no buprenorphine use.
The majority of respondents were female (55%), aged 25–44 years
(72%), and Caucasian/White (90%) (Table 1). Respondents tended to
be from rural/suburban communities (57%) and at least partly em-
ployed (full-time, 56%; part-time, 15%). A variety of health insurance
sources were reported, including private (30%), Medicaid/Medicare
(34%), VA/Military (3%), and dependent (9%). Nearly one-quarter
(24%) reported having no/other insurance coverage.
3.2. Use of buprenorphine prescribed by a physician
More than one-half (54%) of survey respondents reported a lifetime
history of receiving a buprenorphine prescription for OUD. Among
participants who responded to specific questions about aberrant beha-
viors, 38% reported failure to remain completely abstinent while on
buprenorphine and 32% reported not taking buprenorphine only as
prescribed. One-third (33%) admitted they had given away, sold, or
traded some/all of their buprenorphine prescriptions.
Among the 63% of respondents who had ceased buprenorphine use
and who answered why they stopped receiving their most recent bu-
prenorphine prescription, the most common reasons cited were that
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they chose to stop seeing their doctor or lost the ability to visit or pay
for doctor’s visits or prescriptions (Fig. 2). Doctor and patient agree-
ment on treatment program completion was endorsed by 19% of re-
spondents, while 12% reported their doctor stopped prescribing, de-
spite the respondent feeling his/her treatment program was not over.
Over one-quarter of respondents provided open-ended responses for
why their buprenorphine prescription became inactive. Example re-
sponses included the respondent deciding to “go to treatment,”
switching to methadone therapy, incarceration, and viewing bupre-
norphine as a “crutch.”
3.3. Use of buprenorphine without a physician prescription
Among respondents who used diverted buprenorphine (N=175),
68% reported using single-ingredient buprenorphine tablets, 66% used
combination tablets (buprenorphine/naloxone), and 75% used combi-
nation film. Three of the four most common reasons for diverted bu-
prenorphine use were for the intended purposes of the medication,
including to avoid/ease withdrawals, to maintain abstinence from other
drugs, and to try weaning oneself off drugs (Fig. 3). While a majority of
respondents used buprenorphine to get high or to alter their mood, less
than 5% reported buprenorphine as their drug of choice for getting high
or thought that buprenorphine provided a better high than other drugs.
Non-prescription buprenorphine was mostly obtained through a
dealer/street deal, a friend/relative, or a doctor’s prescription (Fig. 4A).
Open-ended responses indicated that methadone clinics and re-
habilitation facilities were also additional venues for obtaining the
drug. Among users of illicitly obtained buprenorphine, most reported
using the drug at least once a day (Fig. 4B), and the most common route
was dissolution under the tongue (Fig. 4C). Snorting, swallowing
whole, and injecting drug were each endorsed by approximately 25% of
respondents.
Qualitative follow-up responses indicated that routes of adminis-
tration other than dissolving under the tongue were used commonly to
heighten or accelerate a high. Respondents stated, “I injected them so
they would hit me faster,” “I injected them to get high, that was my
method of choice for any drug,” and “I would snort or inject it if I
needed to get high or ease withdrawal quicker.” Users would favor
specific formulations depending on their purpose of use. One bupre-
norphine oral film user would “dissolve and snort to get high, dissolve
under tongue to maintain withdrawals,” while a single-ingredient user
would “snort/inject to get high, dissolve under tongue when low
quantity/trying to wean off or avoid withdrawals.”
3.4. Barriers to buprenorphine access
Survey respondents were asked questions regarding difficulty in
obtaining buprenorphine prescriptions, and whether changes in re-
strictions would affect their interest and/or usage of buprenorphine.
Regardless of prior history of buprenorphine use (with or without a
prescription), lack of access to doctors who could legally prescribe
buprenorphine and high out-of-pocket costs were widely endorsed as
barriers to access.
Problems finding a doctor or obtaining a buprenorphine
Fig. 1. Prescription and non-prescription buprenorphine use.
OUD, opioid use disorder; RAPID, Researchers and Participants Interacting Directly; Rx, prescription; SKIP, Survey of Key Informants’ Patients.
Table 1
Characteristics of respondents.





18–24 years 20 (7)
25–34 years 113 (39)
35–44 years 96 (33)
45–54 years 44 (15)





















V A/Military 9 (3)
None/Other 70 (24)
a N-values represent the number of valid responses.
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prescription were reported by respondents who had used diverted bu-
prenorphine (33%) as well as by respondents who did have a pre-
scription (38%). Open-ended responses included: “hard to find and
expensive”; “it’s difficult to find a doc that is taking patients. Or have to
wait a year for a new patient appointment”; “costly to see a doctor who
would prescribe it even with insurance”; “hard to get into program,
long waiting lists”; and “it usually comes down to money [since] some
doctors are cash only to get into their SUBOXONE® program.”
Most (81%) of respondents with any history of using diverted bu-
prenorphine indicated that easier access to a doctor who could pre-
scribe buprenorphine would encourage them to get a prescription ra-
ther than seeking buprenorphine on their own. One respondent stated
that a prescription “…would make the process of obtaining the drug
safer and easier. There would [be] no illegal street deals to get the drugs
and insurance would help me to obtain it for cheaper.” Another stated
that “If it wasn’t so hard to get legally there would most likely be more
people taking it and getting cleaned up than people taking drugs.”
Among all users who ever used buprenorphine (with a prescription or
diverted use), 43% indicated they would use buprenorphine more often
if it was easier to find and more accessible by prescription or through
other sources.
Fig. 2. Reasons for cessation of the most recent buprenorphine prescription.
Fig. 3. Motivations for use among those who used diverted buprenorphine.
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4. Discussion
This survey of 303 patients formerly in treatment for OUD was
conducted to estimate how many had ever used diverted buprenorphine
and explore why this illicit use occurred. Diverted buprenorphine was
prevalent, with 58% of respondents having used diverted buprenor-
phine. Even among a population of patients seeking treatment for
OUD who might be at risk for the abuse or non-medical use of
Fig. 4. Patterns of diverted buprenorphine use.
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buprenorphine, reasons for use of diverted buprenorphine were largely
for indicated therapeutic purposes such as managing withdrawal
symptoms or maintaining abstinence. Buprenorphine diversion was
often driven by issues surrounding barriers to access, and 81% of re-
spondents who used diverted buprenorphine indicated they would be
more encouraged to obtain buprenorphine from a doctor if access im-
proved.
Open-ended responses by participants revealed three main barriers
to buprenorphine access: difficulty in accessing physicians, high cost,
and social stigma. Prescribing physicians were “hard to find” and re-
spondents were often put on long waiting lists while experiencing
withdrawal symptoms that discouraged obtaining buprenorphine leg-
ally. In an analysis by Jones et al. (2015) examining opioid treatment
need and capacity in the US, 96% of states had opioid abuse or de-
pendence rates higher than their buprenorphine treatment capacity. In
2012, only 27.5% of DATA-waived physicians in the United States were
certified for the 100-patient limit, despite the fact that 82.3% of opioid
treatment programs were at ≥80% capacity (Jones et al., 2015). As of
January 2018, based on Substance Abuse and Mental Health Services
Administration (SAMHSA) updates, 20% of DATA-waived physicians
were certified for the 100-patient limit and only 8% were certified for
the newer 275-patient limit.
Expense was another commonly cited issue associated with finding
a prescribing physician. Respondents reported many physicians were
cash only, and despite insurance coverage, some found the cost of bu-
prenorphine therapy to be prohibitive. A conjoint analysis found a
patient’s method of payment was the second largest factor in a physi-
cians’ decision to start buprenorphine therapy in a new patient, second
only to co-occurring substance use (Knudsen et al., 2018). Physicians
had a clear preference for cash-paying patients, and an unwillingness to
accept patients paying with Medicaid. Cash may reduce administrative
burdens associated with Medicaid reimbursement; however, the rea-
sons for a cash preference within physicians is not well understood.
Given the expansion of Medicaid under the Affordable Care Act (ACA),
additional patients seeking treatment for OUD may gain access to
healthcare (McLellan and Woodworth, 2014). If physicians prescribing
buprenorphine are unwilling to accept Medicaid, growth through the
ACA in access to prescribing physicians may be weakened.
It is still unclear how the costs of obtaining buprenorphine through
a doctor’s prescription compare to the costs of obtaining buprenorphine
on the street. While some respondents stated obtaining buprenorphine
legally would lower costs for individual dosages due to insurance
coverage, the cost of the doctor’s visit and/or the limited number of
insurance policies accepted may be prohibitive. The introduction of
generic buprenorphine in 2009 reduced the price of certain formula-
tions, and a 2009 self-administered survey in Providence, RI found that
among 100 opioid users, the majority found buprenorphine/naloxone
to be less expensive than an equivalent amount of heroin or other
prescription opioid (Bazazi et al., 2011). Results from the same survey
indicated that 73% of respondents found obtaining buprenorphine/
naloxone to be easy or very easy. With easy access to cost-effective
buprenorphine formulations readily available on the street, users may
have less incentive to obtain buprenorphine through a doctor’s pre-
scription.
Lastly, the social stigma associated with seeking treatment for OUD
may have prevented some respondents from seeking care. Respondents
frequently expressed that buprenorphine is a “crutch” or that bupre-
norphine is simply a substitution for other opioid addictions. Stigma in
the arena of addiction can contribute to social isolation, undermine
long-term recovery, and reduce help-seeking behaviors (White, 2012).
Reducing social barriers to buprenorphine use may encourage addi-
tional patients to seek treatment for OUD.
A fine line exists between abusing buprenorphine and using diverted
buprenorphine for therapeutic purposes, and it is worth noting that
decreasing barriers to access may also increase diversion for non-ther-
apeutic purposes (Cicero et al., 2007a,b). Buprenorphine inherently
carries a risk for abuse because the mechanism used to prevent with-
drawal is similar in nature to the mechanisms underlying euphoric ef-
fects (Donaher and Welsh, 2006) and users have reported different
ways of manipulating these products to produce better highs and se-
parate buprenorphine from naloxone to generate “pure buprenorphine”
for injection (Cicero et al., 2014). In the current survey, 52% of re-
spondents who used diverted buprenorphine reported having used a
buprenorphine product to get high or alter mood, with snorting and
injection endorsed as common routes of illicit use. However, few re-
spondents indicated that buprenorphine was their drug of choice to get
high. Additional research is needed to better elucidate the dynamic
between treatment benefits and potential abuse with all OUD medica-
tions.
Concern about abuse and diversion is a major barrier affecting
availability of buprenorphine to individuals who need treatment for
OUD. One leading reason why prescribers do not seek a buprenorphine
prescription waiver is the concern about diversion (Huhn and Dunn,
2017). While there are valid reasons for prescribers and policymakers to
be concerned about the potential harm of diverted buprenorphine use,
including local injection site reactions and systemic diseases associated
with injections, overdose (commonly associated with concurrent use of
sedatives such as benzodiazepines and/or alcohol) (Hakkinen et al.,
2012; Tracqui et al., 1998), and unintended exposure to children
(Martin and Rocque, 2011; Pedapati and Bateman, 2011), increased
understanding of the motivations for use of diverted buprenorphine and
the role of unmet treatment needs is important for reducing physicians’
reluctance to prescribe buprenorphine in the midst of an opioid crisis.
Limitations applicable to survey data also apply to this study. This
sample of respondents may not be representative of all opioid users, as
it reflects a convenience sample of unknown sampling frame. Relative
to the SKIP participants, the RAPID sample included lower numbers of
younger and non-white participants (Supplemental Table 1), popula-
tions that may demonstrate different patterns of use than what was
found. These populations may require extra attention for participation
in follow-up studies, which we hope to focus on as our research con-
tinues. The voluntary, self-administered, online nature of this survey
leads to response bias and does not provide a way to probe respondents
further. Moreover, the survey respondents were individuals seeking
medication-assisted treatment for OUD and as such, the results pre-
sented here may not reflect those of the population of buprenorphine
abusers who have never sought or received legitimate OUD treatment.
Despite these weaknesses, this study sample was drawn from a known
drug user population at a higher risk for using drugs illicitly for reasons
outside therapeutic intentions. Underreporting of buprenorphine abuse
is unlikely, as this sample of respondents are in recovery and are likely
seeking opportunities to provide information on opioid use and abuse.
The survey also allowed for the inclusion of open-ended responses,
which mitigated the inability to further probe respondents on their
answers.
While the focus of this study was on a US sample, buprenorphine
abuse and diversion are of global concern. Results from this study were
consistent with a limited number of international studies that indicate
that diverted buprenorphine is often used to prevent withdrawal and
stop use of other opioids (Yokell et al., 2011), and may be due to lack of
access to treatment (Johnson and Richert, 2015). More research is ne-
cessary to understand motivations for use of diverted buprenorphine
internationally, given the extent of use of diverted buprenorphine in the
countries in which buprenorphine is available for the treatment of
opioid use disorder.
5. Conclusions
The findings of this study suggest that those who use diverted bu-
prenorphine prefer obtaining it through a valid prescription. It is im-
portant to find ways to increase access by reducing barriers such as cost,
unavailability of prescribers, and social stigma. Although increased
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buprenorphine availability has potential to increase diversion, the
majority of buprenorphine use in this high-risk population was for the
intended therapeutic purpose of easing and preventing withdrawal,
suggesting that improved prescriber access might provide more po-
tential benefit than harm.
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